Revive Therapeutics Ltd (RVVTF)

[ReikoBlack]

From the same Short Form Prospectus...

Notes

"(1) The $9,000,000 is anticipated to be allocated to cover the following milestones and activities for the Bucillamine Phase 3 clinical study for COVID-19: (i) completion of the 210 patient interim analysis which is expected to be completed in Q1-2021"

That quote could be as you interpret it, or taken to mean those parameters have already been met, ie, between 200-1000 patients have already completed the interim analysis. The statement is broad and non specific so as you indicated earlier....words matter.

Also per LT's post from earlier today re the NDA with the FDA, does that also play into the imprecise wording of this statement???


Quote: "It is estimated that over 200 patients will have completed the study for the interim analysis by the end of the second quarter of 2021."